Established in 1980, taiba was the first company in providing medicines for rare diseases in the Middle East.

Today, we are the leading company in rare diseases with a diverse, innovative portfolio.

Reflecting our commitment to patients, we continue to focus on access to health for patients in our region to reach those in need of our medicines through partnerships.

We have the ability and the responsibility to ensure access to medicines through alliances with research and development companies.

There are millions of people in the Middle East and Africa with rare diseases relying on us. In this part of the world, the highest rate of consanguinity occurs, and we have the highest prevalence rates in the world for rare diseases.

Due to consanguineous marriages, in GCC as Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, these countries are predisposed to metabolic and genetic diseases. Their nationals have free access to healthcare and any treatment that becomes available. Our role is to improve access to patients here and expand access to reach other patients because every patient has the right to health.